This study involves metabolic dysfunction-associated steatohepatitis (MASH), liver fibrosis, liver cirrhosis, and MASH-related hepatocellular carcinoma
Conditions
Interventions
Precancerous lesion and inflammatory bowel disease group:NA
Chronic liver disease group:NA
Hepatocellular carcinoma group:NA
Mesenteric cancer group:NA
Colorectal cancer group:NA
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1.Patients aged 18–90 years who received medical care, surgery, endoscopic biopsy, or pathological examination at West China Hospital, Sichuan University between January 2009 and December 2019. 2.Patients with a clear clinical and/or pathological diagnosis corresponding to the diseases or control conditions involved in this study, including metabolic dysfunction-associated steatohepatitis (MASH), liver fibrosis, liver cirrhosis, hepatocellular carcinoma, colon cancer, rectal cancer, colorectal adenoma, Crohn’s disease, ulcerative colitis, and colorectal cancer-associated mesenteric involvement or metastasis. 3.Availability of formalin-fixed paraffin-embedded tissue blocks or pathological sections suitable for experimental analysis, with sufficient tissue volume for immunohistochemical staining, pathological review, and experimental quality control. For tumor cases, priority will be given to cases with paired adjacent non-tumor tissue, distal non-tumor tissue, or adjacent non-tumor mesenteric tissue. 4.Availability of complete or relatively complete clinicopathological, treatment, and follow-up data, including age, sex, diagnosis, lesion site, pathological type, tumor stage, treatment modality, underlying diseases, postoperative outcomes, survival time, or recurrence status. 5.For patients included in the immunotherapy response analysis, patients must have received systemic therapy based on PD-1/PD-L1 inhibitors and have pretreatment tumor tissue samples available for analysis, as well as evaluable treatment response data.
Exclusion criteria
Exclusion criteria: 1.Patients younger than 18 years or older than 90 years. 2.Patients with unclear clinical or pathological diagnoses, or those who do not meet the disease types or control conditions defined in this study. 3.Tissue samples that do not meet the experimental requirements, including insufficient tissue volume, severe autolysis, excessive necrosis, poor fixation or embedding quality, or unsatisfactory section quality. 4.Patients with severely incomplete clinicopathological, treatment, or follow-up data, making effective grouping, clinical correlation analysis, or prognostic analysis impossible. 5.Patients who received preoperative radiotherapy, chemotherapy, targeted therapy, or immunotherapy that may significantly affect NRF2 expression or pathological assessment; this does not apply to patients included in the immunotherapy response analysis cohort. 6.Samples whose source, permission for use, or ethical requirements do not comply with the regulations of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NRF2 expression level and subcellular localization; | — |
Secondary
| Measure | Time frame |
|---|---|
| Association between NRF2 expression and clinicopathological characteristics;Survival outcomes; | — |
Countries
China
Contacts
Public ContactLi Gu
West China Hospital of Sichuan University
Outcome results
None listed